Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AG-80308 in Dry Eye Disease
NCT05372107Phase 1Completed
- Sponsor
- Allgenesis Biotherapeutics
- Start
- Jun 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AGN-232411 in dry eye disease (DED) (4 arms), sponsored by Allgenesis Biotherapeutics. Primary endpoint: Evaluation of adverse events (AEs) and serious AEs (SAEs). Started Jun 2022; status: completed.
02
Drugs
AGN-232411
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT05372107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05372107.